---
schema_version: "secwatch.filing_event.v1"
accession: "0001937653-25-000012"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2025-03-05T23:59:59+00:00"
generated_at: "2026-05-25T11:33:38.033072+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zymeworks reports $122.7M net loss for 2024; Ziihera approval drives $25M milestone

## Summary
- Revenue $76.3M in 2024 (vs $76.0M in 2023); net loss $122.7M vs $118.7M loss prior year.
- Cash resources $324.2M at Dec 31, 2024; projected runway into 2H-2027 with anticipated regulatory milestones.
- Ziihera (zanidatamab) FDA approved for HER2+ BTC in Nov 2024; initial net sales $1.1M; $25M milestone earned from Jazz.
- Phase 1 studies initiated for ZW191 and ZW171; IND for ZW251 accelerated to mid-2025; ZW220 preparations paused.
- Non-cash impairment charge of $17.3M for discontinuation of zanidatamab zovodotin; $14M milestone from GSK in Jan 2025.

## SEC filing metadata
- accession: 0001937653-25-000012
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2025-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000193765325000012/0001937653-25-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000193765325000012/zyme-20250305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001937653-25-000012
- JSON: https://secwatch.observer/filing/0001937653-25-000012.json
- Plain text: https://secwatch.observer/filing/0001937653-25-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.